Klaria Pharma Holding AB (publ) announced that Jesper Wiklund is leaving the CEO position to focus on other activities based in Germany. Fredrik Hübinette, the company's chairman of the board, will assume the position as acting CEO with immediate effect during a transition period. During the autumn, Klaria has intensified the work of identifying and signing agreements with one or more partners for the company's migraine product Sumatriptan Alginate Film.

At the same time, the process of obtaining market approval for the product continues, and the company expects to obtain market approvals in several European markets during the second half of 2024.